Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06747-1 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Daniela Weiler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland. daniela.weiler@luks.ch. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Proto-Oncogene Proteins c-ret, Pyrazoles, Pyridines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departement of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland. daniela.weiler@luks.ch.
- Departement of Nuclear Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland.
ORCID-Profile: Daniela Weiler, Maria Del Sol Pérez Lago
Zitieren
APA
Weiler, D., & Pérez Lago, M. D. S. (2024). Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06747-1
Vancouver
Weiler D, Pérez Lago MDS. Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06747-1
BibTeX
@article{Weiler2024,
author = {Weiler, Daniela and Pérez Lago, Maria Del Sol},
title = {Successful radioiodine redifferentiation with selpercatinib in RET fusion-positive papillary thyroid carcinoma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06747-1}
}
EUVIMED